Loading
Hospitals often lack the staff to switch patients to cheaper equivalent drugs. Private investors could fund the switching teams and be repaid by the health system from the money saved.
Switching programmes (pharmacists, patient information, prescribing system changes) return far more in drug savings than they cost, but compete for scarce operating budgets. A social impact bond raises private capital to fund the programme and repays investors, with a return, from verified savings measured against a pre-agreed baseline; the payer pays only if savings materialise. Social impact bonds have been used in social care and public health; oncology drug switching has an unusually measurable outcome.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.